Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferric maltol in iron deficiency anemia with chronic kidney disease
NCT02968368Phase 3Completed
- Sponsor
- Shield Therapeutics plc
- Start
- Dec 2016
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in iron deficiency anemia (IDA) comparing Oral ferric maltol with Oral placebo (2 arms). Primary endpoint: Change in Hemoglobin Concentration From Baseline to Week 16. Started Dec 2016; status: completed.
02
Drugs
ferric maltol
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT02968368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02968368.